Anthem Biosciences Unveils Rs 3,395-Crore IPO Plans

Anthem Biosciences has filed for a Rs 3,395-crore IPO consisting entirely of an offer for sale by promoters and shareholders. The funds will not benefit the company directly but go to selling parties. Anthem specializes in CRDMO with significant manufacturing capabilities and reported significant financial growth recently.

Anthem Biosciences, a pioneering entity in the realm of innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organization (CRDMO), has filed preliminary documents with the Securities and Exchange Board of India (Sebi) to initiate a Rs 3,395-crore initial public offering (IPO).

The entire IPO is structured as an offer for sale (OFS), with no financial gains from the issuance directed towards the company itself. Instead, the proceeds will be distributed among the promoters, investors, and other key shareholders venturing to offload their stakes in Anthem Biosciences.

Established in Bengaluru, Anthem Biosciences boasts extensive manufacturing facilities in Karnataka, with expansion plans underway. In tandem with a 34.3% rise in revenue, the organization stands as a frontrunner in manufacturing and sale of specialized pharmaceutical ingredients, underlining its robust market presence and future potential.

(With inputs from agencies.)